TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
The Pharma Data
JULY 11, 2021
3 These data are being presented at the 2021 European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress in Krakow, Poland and Madrid, Spain. TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. percent (-100; 852.8), and the median reduction was 97.7 Interactions.
52 
Let's personalize your content